Oric Pharmaceuticals ORIC Institutional Ownership

Updated Oct 11, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) was held by 182 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total holdings of ORIC shares rose 3.52% from Q1 2026, and the holder count rose 30.94% from Q2 2025.
• Of the 182 holders of ORIC in Q2 2026, 114 added to their positions, 42 reduced their stakes and 26 left their positions unchanged.
• In total, institutional investors held 123.55Mn shares of Oric Pharmaceuticals at the end of Q2 2026, up 4.2Mn from the prior quarter and up 31.99Mn from a year earlier.
• Nextech Invest Ltd. held the largest position in ORIC at 7.16Mn shares as of June 30, 2026.
• The biggest increases in ORIC positions during Q2 2026 came from D. E. Shaw & Co., Inc. (+1.54Mn shares), AIHC Capital Management Ltd (+1.37Mn shares), T. Rowe Price Associates Inc (+1.23Mn shares), State Street Corp (+1.19Mn shares) and Algert Global LLC (+1.08Mn shares).
• The largest position reductions in ORIC for Q2 2026 were by Pfizer Inc (-4.41Mn shares), Alkeon Capital Management LLC (-765K shares), Viking Global Investors LP (-697.77K shares), OrbiMed Advisors LLC (-678.93K shares) and Balyasny Asset Management L.P. (-499.59K shares).
• According to Business Quant data, the leading holders of ORIC for Q2 2026 were Nextech Invest Ltd. (7.16Mn shares), BlackRock, Inc. (6.82Mn shares), EcoR1 Capital, LLC (6.73Mn shares), T. Rowe Price Associates Inc (6.62Mn shares), Viking Global Investors LP (5.13Mn shares), State Street Corp (4.89Mn shares), SR One Capital Management, LP (4.62Mn shares), Venrock Adviser, LLC (4.32Mn shares), NEA Management Company, LLC (4.12Mn shares) and Vanguard Capital Management LLC (3.95Mn shares).